HighTide TherapeuticsHTTIF 14 Cash Ratio is 5.11 as of Dec. 2025, which is at its 10-year median of 5.11. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,388 Biotechnology companies, HighTide Therapeutics ranks better than 64.41% on this metric.
HighTide Therapeutics has a Cash Ratio of 5.11. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for HighTide Therapeutics's Cash Ratio or its related term are showing as below:
HTTIF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.64 Med: 5.11 Max: 26.82
Current: 5.11
During the past 5 years, HighTide Therapeutics's highest Cash Ratio was 26.82. The lowest was 0.64. And the median was 5.11.
HTTIF's Cash Ratio is ranked better than 64.41% of 1388
companies
in the Biotechnology industry
Industry Median: 2.93
vs HTTIF: 5.11
HighTide Therapeutics (OTCPK:HTTIF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HighTide Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HighTide Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where HighTide Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HighTide Therapeutics (HTTIF) has a Cash Ratio of 5.11 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on HighTide Therapeutics and its competitors. This is near median its historical median of 5.11. Over the past decade, HighTide Therapeutics' Cash Ratio has ranged from 0.64 to 26.82. According to the industry distribution chart, HighTide Therapeutics ranks #494 out of 1388 companies in the Biotechnology industry, placing it in the top 35.6%.
Is HighTide Therapeutics' Cash Ratio too high?
HighTide Therapeutics' current Cash Ratio of 5.11 is near median its 10-year median of 5.11. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 26.82. The Biotechnology industry median Cash Ratio is 2.93. HighTide Therapeutics' value of 5.11 is 74.4% above this industry median. Based on the distribution chart, HighTide Therapeutics ranks #494 out of 1388 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HighTide Therapeutics ranks #494 out of 1388 companies for Cash Ratio. This puts HighTide Therapeutics in the upper half of its industry. The industry median Cash Ratio is 2.93. HighTide Therapeutics' value of 5.11 is 74.4% above this benchmark. Historically, HighTide Therapeutics' own Cash Ratio has ranged from 0.64 to 26.82 over the past decade. While the company's 10-year median is 5.11 vs. the industry median of 2.93, HighTide Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HighTide Therapeutics's current Cash Ratio of 5.11 is 74.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on HighTide Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HighTide Therapeutics's current Cash Ratio is 5.11, which is near median its own 10-year median of 5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Cash Ratio of 5.11. The current Cash Ratio is 5.11, which is near median its 10-year median of 5.11 and 74.4% above the Biotechnology industry median of 2.93. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Cash Ratio is 5.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score
Get the complete analysis for HTTIF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTTIF has been successfully added to your 
